参考文献/References:
[1] Richette P,Bardin T.Gout[J]. Lancet,2009,375(9711):318-328.DOI:10.1016/S0140-6736(09)60883-7.
[2] 王靖宇, 常宝成. 高尿酸血症/痛风流行病学特点及危险因素[J]. 国际内分泌代谢杂志, 2016,36(2):78-81.DOI:10.3760/cma.j.issn.1673-4157.2016.02.002.
[3] Doyle LA, Yang W, Abruzzo LV, et al. A multidrug resistance transporter from human MCF-7 breast cancer cells[J].Proc Natl Acad Sci U S A,1998,95(26):15665-15670.
[4] Wong K, Briddon SJ, Holliday ND,et al.Plasma membrane dynamics and tetrameric organisation of ABCG2 transporters in mammalian cells revealed by single particle imaging techniques[J].Biochim Biophys Acta,2016,1863(1):19-29. DOI:10.1016/j.bbamcr.2015.10.002.
[5] Sarankó H, Tordai H, Telbisz Á,et al.Effects of the gout-causing Q141K polymorphism and a CFTR ΔF508 mimicking mutation on the processing and stability of the ABCG2 protein[J].Biochem Biophys Res Commun,2013,437(1):140-145. DOI:10.1016/j.bbrc.2013.06.054.
[6] Ripperger A, Benndorf RA. The C421A(Q141K)polymorphism enhances the 3'-untranslated region(3'-UTR)-dependent regulation of ATP-binding cassette transporter ABCG2[J].Biochem Pharmacol,2016,104:139-147.DOI:10.1016/j.bcp.2016.02.011.
[7] Huls M, Brown CD, Windass AS, et al. The breast cancer resistance protein transporter ABCG2 is expressed in the human kidney proximal tubule apical membrane[J].Kidney Int,2008,73(2):220-225. DOI:10.1038/sj.ki.5002645.
[8] Fetsch PA, Abati A, Litman T,et al. Localization of the ABCG2 mitoxantrone resistance-associated protein in normal tissues[J].Cancer Lett,2006,235(1):84-92. DOI:10.1016/j.canlet.2005.04.024.
[9] Westover D, Li F. New trends for overcoming ABCG2/BCRP-mediated resistance to cancer therapies[J].J Exp Clin Cancer Res,2015,34:159. DOI: 10.1186/s13046-015-0275-x.
[10] Atisha-Fregoso Y,Lima G,Pascual-Ramos V,et al. Rheumatoid arthritis disease activity is determinant for ABCB1 and ABCG2 drug-efflux transporters function[J].PLoS One,2016,11(7):e0159556.DOI:10.1371/journal.pone.0159556.
[11] Tsuchiya K, Hayashida T,Hamada A,et al. Low raltegravir concentration in cerebrospinal fluid in patients with ABCG2 genetic variants[J].J Acquir Immune Defic Syndr,2014,66(5):484-486. DOI:10.1097/QAI.0000000000000222.
[12] Bauer M, Römermann K,Karch R,et al. Pilot PET study to assess the functional interplay between ABCB1 and ABCG2 at the human Blood-brain barrier[J].Clin Pharmacol Ther, 2016,100(2):131-141. DOI:10.1002/cpt.362.
[13] Kumar JS, Wei BR, Madigan JP, et al. Bioluminescent imaging of ABCG2 efflux activity at the blood-placenta barrier[J].Sci Rep,2016,6:20418. DOI:10.1038/srep20418.
[14] Klein DM,Cherrington NJ. Organic and inorganic transporters of the testis: a review[J].Spermatogenesis,2015,4(2):e979653. DOI:10.4161/21565562.2014.979653.
[15] Woodward OM, Köttgen A, Coresh J, et al. Identification of a urate transporter, ABCG2, with a common functional polymorphism causing gout[J].Proc Natl Acad Sci U S A, 2009,106(25):10338-10342. DOI:10.1073/pnas.0901249106.
[16] Woodward OM, Köttgen A, Köttgen M. ABCG transporters and disease[J].FEBS J,2011,278(18):3215-3225. DOI:10.1111/j.1742-4658.2011.08171.x.
[17] Takada T, Ichida K, Matsuo H,et al. ABCG2 dysfunction increases serum uric acid by decreased intestinal urate excretion[J].Nucleosides Nucleotides Nucleic Acids,2014,33(4-6):275-281. DOI: 10.1080/15257770.2013.854902.
[18] 吴蕾, 何耀, 张迪. ABCG2基因rs2231142位点基因多态性与东亚人群痛风相关性研究的Meta分析[J]. 中华流行病学杂志, 2015,36(11):1291-1296.DOI:10.3760/cma.j.issn.0254-6450.2015.11.022.
[19] 余家会, 何霞, 张蓓,等. 新疆地区维吾尔族和汉族人群ABCG2基因rs2231142位点多态性与高尿酸血症的相关性[J]. 临床检验杂志, 2015, 33(2):142-146.DOI:10.13602/j.cnki.jcls.2015.02.16.
[20] Kim YS, Kim Y, Park G, et al. Genetic analysis of ABCG2 and SLC2A9 gene polymorphisms in gouty arthritis in a Korean population[J].Korean J Intern Med,2015,30(6):913-920. DOI:10.3904/kjim.2015.30.6.913.
[21] Dong Z, Guo S, Yang Y, et al. Association between ABCG2 Q141K polymorphism and gout risk affected by ethnicity and gender: a systematic review and meta-analysis[J].Int J Rheum Dis,2015,18(4):382-391. DOI:10.1111/1756-185X.12519.
[22] Huffman JE, Albrecht E, Teumer A,et al. Modulation of genetic associations with serum urate levels by body-mass-index in humans[J].PLoS One,2015,10(3):e0119752. DOI:10.1371/journal.pone.0119752.
[23] Matsuo H, Ichida K, Takada T, et al. Common dysfunctional variants in ABCG2 are a major cause of early-onset gout[J].Sci Rep,2013,3:2014. DOI: 10.1038/srep02014.
[24] Stiburkova B, Miyata H, Závada J,et al. Novel dysfunctional variant in ABCG2 as a cause of severe tophaceous gout: biochemical, molecular genetics and functional analysis[J].Rheumatology(Oxford),2016,55(1):191-194. DOI:10.1093/rheumatology/kev350.
[25] Li R, Miao L, Qin L, et al. A meta-analysis of the associations between the Q141K and Q126X ABCG2 gene variants and gout risk[J].Int J Clin Exp Pathol,2015,8(9):9812-9823.
[26] Burke BT, Köttgen A, Law A, et al. Gout in older adults: the atherosclerosis risk in communities study[J].J Gerontol A Biol Sci Med Sci,2016,71(4):536-542. DOI:10.1093/gerona/glv120.
[27] He W, Phipps-Green A, Stamp LK, et al. Population-specific association between ABCG2 variants and tophaceous disease in people with gout[J].Arthritis Res Ther,2017,19(1):43. DOI:10.1186/s13075-017-1254-8.
[28] Roberts RL, Wallace MC, Phipps-Green AJ, et al. ABCG2 loss-of-function polymorphism predicts poor response to allopurinol in patients with gout[J].Pharmacogenomics J, 2017,17(2):201-203. DOI:10.1038/tpj.2015.101.
[29] 李静. 复方土茯苓颗粒治疗痛风患者高尿酸血症疗效及基于ABCG2降尿酸机制研究[D]. 广州中医药大学, 2016.
[30] 卢芳, 周琦, 张颖,等. 基于痛风性关节炎ABCG2尿酸转运靶点的穿山龙调控机制研究[J]. 中华中医药学刊, 2016,34(5):1057-1061.DOI:10.13193/j.issn.1673-7717.2016.05.010.
[31] 施琬, 李钟, 顾祖莲,等. 虎杖-桂枝药对配伍对大鼠慢性高尿酸血症和肾、肠尿酸转运体表达的影响[J]. 中国实验方剂学杂志,2016,22(2):107-112.DOI:10.13422/j.cnki.syfjx.2016020107.
相似文献/References:
[1]张睿,刘帅辉,于珮.痛风合并慢性肾脏疾病的药物治疗[J].国际内分泌代谢杂志,2016,36(02):82.[doi:10.3760/cma.j.issn.1673-4157.2016.02.003]
Zhang Rui,Liu Shuaihui,Yu Pei..Drug therapy of gout combined with chronic kidney disease[J].International Journal of Endocrinology and Metabolism,2016,36(06):82.[doi:10.3760/cma.j.issn.1673-4157.2016.02.003]
[2]周宇,柯甦捷,刘礼斌.血尿酸与糖尿病肾病[J].国际内分泌代谢杂志,2016,36(03):202.[doi:10.3760/cma.j.issn.1673-4157.2016.03.15]
Zhou Yu,Ke Sujie,Liu Libin..Serum uric acid and diabetic nephropathy[J].International Journal of Endocrinology and Metabolism,2016,36(06):202.[doi:10.3760/cma.j.issn.1673-4157.2016.03.15]
[3]李树颖,孙丽荣.膳食营养与高尿酸血症和痛风的关系[J].国际内分泌代谢杂志,2016,36(04):223.[doi:10.3760/cma.j.issn.1673-4157.2016.04.03]
Li Shuying,Sun Lirong.Relationship between dietary nutrients and hyperuricemia and gout[J].International Journal of Endocrinology and Metabolism,2016,36(06):223.[doi:10.3760/cma.j.issn.1673-4157.2016.04.03]
[4]安秀敏 蔡婷婷 缪珩.2型糖尿病患者血尿酸与血栓弹力图的
相关性分析[J].国际内分泌代谢杂志,2018,38(04):217.[doi:10.3760/cma.j.issn.1673-4157.2018.04.001]
An Xiumin,Cai Tingting,Miao Heng..Correlation between serum uric acid and thrombelastogram in patients with type 2 diabetes[J].International Journal of Endocrinology and Metabolism,2018,38(06):217.[doi:10.3760/cma.j.issn.1673-4157.2018.04.001]
[5]高忠爱 韩菲 袁欣欣 孙梦迪 李晓晨 刘然 姜文慧 张立弋 常宝成 杨菊红.2型糖尿病合并不同类型高尿酸血症的
临床特征及危险因素分析[J].国际内分泌代谢杂志,2018,38(02):73.[doi:10.3760/cma.j.issn.1673-4157.2018.02.001]
Gao Zhongai,Han Fei,Yuan Xinxin,et al.Analysis of clinical characteristics and risk factors of different types of hyperuricemia in patients with type 2 diabetes[J].International Journal of Endocrinology and Metabolism,2018,38(06):73.[doi:10.3760/cma.j.issn.1673-4157.2018.02.001]
[6]孔晓艳 鲁一兵.SGLT2抑制剂对2型糖尿病患者血尿酸水平的影响[J].国际内分泌代谢杂志,2020,40(02):97.[doi:10.3760/cma.j.issn.1673-4157.2020.02.006]
Kong Xiaoyan,Lu Yibing.Effect of SGLT2 inhibitors on serum uric acid level in patients with type 2 diabetes mellitus[J].International Journal of Endocrinology and Metabolism,2020,40(06):97.[doi:10.3760/cma.j.issn.1673-4157.2020.02.006]